Resistance Publications from June 2008 to July 2008
Journals
Title
1) Genetic basis of variation in
tenofovir drug susceptibility in
HIV-1
2) Outcomes of multidrug-resistant
patients switched from enfuvirtide
to raltegravir within a virologically
suppressive regimen. (Research
Letters)
3) Expected response to protease
inhibitors of HIV-1 non-B subtype
viruses according to resistance
algorithms. (Research Letters)
4) Discrepancies in Assignment of
Subtype/Recombinant Forms by
Genotyping Programs for HIV
Type 1 Drug Resistance Testing
May Falsely Predict
Superinfection.
5) Genetic Diversity of Integrase (IN)
Sequences in Antiretroviral
Treatment-Naive and TreatmentExperienced HIV Type 2 Patients.
6) Phylogenetic Diversity and Low
Level Antiretroviral Resistance
Mutations in HIV Type 1
Treatment-Naive Patients from
Cape Town, South Africa.
7) Profile of Primary Resistance in
Human Immunodeficiency Virus
Type 1 (HIV-1)-Infected
Treatment-Naive Individuals from
Western India.
8) Profiling Resistance-Related
Mutations in the Protease Region
of the pol Gene: Single Genome
Sequencing of HIV in Plasma and
Peripheral Blood Mononuclear
Cells.
9) Virologic and Immunologic
Response to Antiretroviral
Therapy and Predictors of HIV
Type 1 Drug Resistance in
Children Receiving Treatment in
Abidjan, Côte d'Ivoire.
10) Molecular Epidemiology of HIV
Type 1 in Newly Diagnosed
Patients in Southern Spain
Lead author
Link
Murray, Robert J
AIDS - June 19, 2008,
Volume 22, Issue 10
Harris, Marianne
AIDS - June 19, 2008,
Volume 22, Issue 10
Champenois, Karen
AIDS - May 31,2008, Volume
22, Issue 9
Ntemgwa M
AIDS Research and Human
Retroviruses (EPub ahead of
print)
Xu L
AIDS Research and Human
Retroviruses (EPub ahead of
print)
Jacobs GB
AIDS Research and Human
Retroviruses (EPub ahead of
print)
Lall M
AIDS Research and Human
Retroviruses (EPub ahead of
print)
Guimaraes AP
AIDS Research and Human
Retroviruses (EPub ahead of
print)
Adje-Toure C
AIDS Research and Human
Retroviruses (EPub ahead of
print)
Michael J.
McConnell
AIDS Research and Human
Retroviruses, 1 June 2008,
Volume 24 Issue 6
11) Antiretroviral Resistance among
HIV Type 1-Infected Women First
Exposed to Antiretrovirals during
Pregnancy: Plasma versus
PBMCs
12) Full-Length HIV Type 1 Proviral
Sequencing of 10 Highly Exposed
Women from Nairobi, Kenya
Reveals a High Proportion of
Intersubtype Recombinants
13) HIV Type 2 Protease, Reverse
Transcriptase, and Envelope Viral
Variation in the PBMC and Genital
Tract of ARV-Naive Women in
Senegal
14) Plasma HIV RNA Decline and
Emergence of Drug Resistance
Mutations among Patients with
Multiple Virologic Failures
Receiving Resistance TestingGuided HAART
15) Study of the Genotypic Resistant
Pattern in HIV-Infected Women
and Children from Rural West
Cameroon
16) Transmitted Antiretroviral Drug
Resistance Surveillance among
Newly HIV Type 1-Diagnosed
Women Attending an Antenatal
Clinic in Entebbe, Uganda
17) Prevalence of reverse
transcriptase and protease
mutations associated with
antiretroviral drug resistance
among drug-naïve HIV-1 infected
pregnant women in Kagera and
Kilimanjaro regions, Tanzania.
18) Mutations in Human
Immunodeficiency Virus Type 1
Integrase Confer Resistance to
the Naphthyridine L-870,810 and
Cross-Resistance to the Clinical
Trial Drug GS-9137
19) Modelled in vivo HIV fitness under
drug selective pressure and
estimated genetic barrier towards
resistance are predictive for
virological response
20) HIV-1-resistant strains during 8week on 8-week off intermittent
therapy and their effect on CD4+
T-cell counts and antiviral
response
Luis E. SotoRamirez
AIDS Research and Human
Retroviruses, 1 June 2008,
Volume 24, Issue 6
Allison M. Land
AIDS Research and Human
Retroviruses, 1 June 2008,
Volume 24, Issue 6
Geoffrey S. Gottlieb
AIDS Research and Human
Retroviruses, 1 June 2008,
Volume 24, Issue 6
Valerio Tozzi
AIDS Research and Human
Retroviruses, 1 June 2008,
Volume 24, Issue 6
Ombretta Turriziani
AIDS Research and Human
Retroviruses, 1 June 2008,
Volume 24, Issue 6
N. Ndembi
AIDS Research and Human
RetroViruses, 1 June 2008,
Volume 24, Issue 6
Nyombi BM
AIDS Research and Therapy,
June 2008, Volume 21, Issue
5
Anneleen
Hombrouck
Antimicrobial Agents and
Chemotherapy, June 2008,
Volume 52, Issue 6
Koen Deforche
Antiviral Therapy, 2008,
Volume 13, Issue 3
Jacques Izopet
Antiviral Therapy, 2008,
Volume 13, Issue 4
21) Prevalence and risk factors for
etravirine resistance among
patients failing on non-nucleoside
reverse transcriptase inhibitors
Giuseppe Lapadula
Antiviral Therapy, 2008,
Volume 13, Issue 4
Carmen de Mendoza
Clinical Infectious Diseases,
1 June 2008, Volume 46,
Issue 11
Martin S. Hirsch
Clinical Infectious Diseases,
15 July 2008, Volume 47,
Issue 2
Cane P
HIV Medicine (EPub ahead
of print)
Street EJ
International Journal of STD
and AIDS, June 2008,
Volume 19, Issue 6
Zimmer, JM
JAIDS, 1 July 2008, Volume
48, Issue 3
Bannister, Wendy P
JAIDS, 1 July 2008, Volume
48, Issue 3
Winters, Bart
JAIDS, 1 May 2008, Volume
48, Issue 1
Assoumou L
Journal of Infectious
Diseases (EPub ahead of
print)
Viviane D. Lima
Journal of Infectious
Diseases, July 2008, Volume
198, Issue 1
Anne Margrethe
Audelin
Journal of Medical Virology,
August 2008, Volume 80,
Issue 8
32) Unexpected dramatic increase in
CD4+ cell count in a patient with
AIDS after enfuvirtide treatment
despite persistent viremia and
resistance mutations
Alessandro Soria
Journal of Medical Virology,
June 2008, Volume 80, Issue
6
33) Zidovudine with nevirapine for the
prevention of HIV mother-to-child
transmission reduces nevirapine
resistance in mothers from the
G.U. van Zyl
Journal of Medical Virology,
June 2008, Volume 80, Issue
6
22) Changing Patterns in HIV Reverse
Transcriptase Resistance
Mutations after Availability of
Tenofovir
23) Antiretroviral Drug Resistance
Testing in Adult HIV-1 Infection:
2008 Recommendations of an
International AIDS Society-USA
Panel
24) Genotypic antiretroviral drug
resistance testing at low viral
loads in the UK.
25) An audit of baseline HIV-1
genotypic resistance testing in a
UK provincial city.
26) Impact on Replicative Fitness of
the G48E Substitution in the
Protease of HIV-1: An In Vitro and
In Silico Evaluation.
27) Transmitted Drug Resistant HIV-1
and Association With Virologic
and CD4 Cell Count Response to
Combination Antiretroviral
Therapy in the EuroSIDA Study.
28) Determination of Clinically
Relevant Cutoffs for HIV-1
Phenotypic Resistance Estimates
Through a Combined Analysis of
Clinical Trial and Cohort Data.
29) Initiatives for Developing and
Comparing Genotype
Interpretation Systems: External
Validation of Existing Systems for
Didanosine against Virological
Response.
30) Increased Resilience to the
Development of Drug Resistance
with Modern Boosted Protease
Inhibitor-Based Highly Active
Antiretroviral Therapy
31) Follow-up of a multi-drug resistant
HIV-1 infected patient successfully
treated with darunavir and
etravirine
Western Cape, South Africa
34) Effect of Flap Mutations on
Structure of HIV-1 Protease and
Inhibition by Saquinavir and
Darunavir.
35) Analysis of Natural Sequence
Variation and Covariation in
Human Immunodeficiency Virus
Type-1 Integrase
36) Comparison of G-to-A Mutation
Frequencies Induced by
APOBEC3 Proteins in H9 Cells
and Peripheral Blood
Mononuclear Cells in the Context
of Impaired Processivities of DrugResistant Human
Immunodeficiency Virus Type 1
Reverse Transcriptase Variants
37) Selection of T1249-Resistant
Human Immunodeficiency Virus
Type 1 Variants
38) Structural Analysis of Human
Immunodeficiency Virus Type 1
CRF01_AE Protease in Complex
with the Substrate p1-p6
39) An Alteration of Human
Immunodeficiency Virus gp41
Leads to Reduced CCR5
Dependence and CD4
Independence
40) Persistence of Transmitted Drug
Resistance among Subjects with
Primary Human Immunodeficiency
Virus Infection
41) Ninety-Nine Is Not Enough:
Molecular Characterization of
Inhibitor-Resistant Human
Immunodeficiency Virus Type 1
Protease Mutants with Insertions
in the Flap Region
42) Highly diversified multiply drugresistant HIV-1 quasispecies in
PBMCs: a case report
43) Impact of HIV-1 protease
mutations A71V/T and T74S on
M89I/V-mediated protease
inhibitor resistance in subtype G
isolates
44) Clinically validated mutation
scores for HIV-1 resistance to
fosamprenavir/ritonavir
45) HIV-1 drug resistance genotyping
from dried blood spots stored for 1
year at 4°C
46) Long-term (4 years) efficacy of
lopinavir/ritonavir monotherapy for
maintenance of HIV suppression.
Liu F
Journal of Molecular Biology
(EPub ahead of print)
Myers RE, Pillay D
Journal of Virology (EPub
ahead of print)
Stefanie Andrea
Knoepfel
Journal of Virology, July
2008, Volume 82, Issue 13
Dirk Eggink
Journal of Virology, July
2008, Volume 82, Issue 13
Rajintha M.
Bandaranayake
Journal of Virology, July
2008, Volume 82, Issue 13
Brian M. Taylor
Journal of Virology, June
2008, Volume 82, Issue 11
Susan J Little
Journal of Virology, June
2008, Volume 82, Issue 11
Milan Koiek
Journal of Virology, June
2008, Volume 82, Issue 12
Yudong Quan
Retrovirology, 30 May 2008,
Volume 5, Issue 43
Luis M. F. Gonzalez
The Journal of Antimicrobial
Chemotherapy, Jule 2008,
Volume 61, Issue 6
B. Masquelier
Ae S. Youngpairoj
Federico Pulido
The Journal of Antimicrobial
Chemotherapy, June 2008,
Volume 61, Issue 6
The Journal of Antimicrobial
Chemotherapy, June 2008,
Volume 61, Issue 6
The Journal of Antimicrobial
Chemotherapy, June 2008,
Volume 61, Issue 6
47) The involvement of HIV-1 RNAse
H in resistance to nucleoside
analogues
48) Restoration of the antiviral activity
of 3'-azido-3'-deoxythymidine
(AZT) against AZT-resistant
human immunodeficiency virus by
delivery of engineered thymidylate
kinase to T cells
49) Recombination increases human
immunodeficiency virus fitness,
but not necessarily diversity
Bénédicte
Roquebert
The Journal of Antimicrobial
Chemotherapy, May 2008,
Volume 61, Issue 5
Arnon Lavie
The Journal of General
Virology, July 2008, Volume
89, Issue 7
N. N. V. Vijay
The Journal of General
Virology, June 2008, Volume
89, Issue 6
Conference Abstracts
Title
1) Abstracts from the 6th European
HIV Resistance Workshop
Lead author
Link
Various
26-28 March 2008, Budapest,
Hungary
Various
Sitges, Spain 10-14 June
2008
M Nalam
CROI February 2008, Boston
4) Connection Domain Mutations
N348I and A360V in HIV-1 RT
Selectively Facilitate Excision of
AZT by Improving Access to
Transiently Formed RNA/DNA
Hybrids
G Beilhartz
CROI February 2008, Boston
5) Emergence of HIV-1 Drug
Resistance among Breastfeeding
Infants Born to HIV-infected
Mothers Taking Antiretrovirals for
Prevention of Mother-to-Child
Transmission of HIV: The Kisumu
Breastfeeding Study, Kenya
Clement Zeh
CROI February 2008, Boston
6) Mechanism by which N348I in HIV1 Reverse Transcriptase Confers
Dual Zidovudine/Nevirapine
Resistance
Soo-Huey Yap
CROI February 2008, Boston
7) Molecular Mechanisms for 3’Azido-3’-Dideoxythymidineresistance Conferred by Mutations
in the Connection and RNase H
Domains of HIV-1 Reverse
Transcriptase
Jessica Brehm
CROI February 2008, Boston
8) Presence of Minor Populations of
Y181C Mutants Detected by Allelespecific PCRand Risk of Efavirenz
Failure in Treatment-naïve
Patients: Results of an ACTG 5095
Case-cohort Study
Roger Paredes
CROI February 2008, Boston
9) The TEmAA ANRS 12109 Phase II
Trial, Step 1: Tolerance and Viral
Resistance after Single-dose
Nevirapine and Short-course of
Tenofovir Disoproxil Fumarate and
Emtricitabine to Prevent Mother-toChild Transmission of HIV-1
Elise Arrive
CROI February 2008, Boston
2) Abstracts presented at XVII
International Drug Resistance
Workshop
3) Circumventing Drug Resistance:
Using the Substrate Envelope
Hypothesis to Develop Robust
Novel HIV-1 Protease Inhibitors
10) Timing of Infection Is Critical for
Nevirapine Resistance Outcomes
among Breastfed Subtype C HIV1-infected Infants Exposed to
Extended vs Single-dose
Nevirapine Prophylaxis: The India
SWEN Study
Anitha Moorthy
CROI February 2008, Boston